Untargeted Metabolomics for the Diagnosis of Exocrine Pancreatic Insufficiency in Chronic Pancreatitis
MetadataShow full item record
AuthorDiaz, Caridad; Jiménez Luna, Cristina; Diéguez Castillo, Carmelo; Martín, Ariadna; Prados Salazar, José Carlos; Martín Ruiz, José Luis; Genilloud, Olga; Vicente, Francisca; Pérez del Palacio, José; Caba Pérez, Octavio
MetabolomicsExocrine pancreatic insufficiencyChronic pancreatitisBiomarkersDiagnosisHigh-resolution mass spectrometry
Díaz, C.; Jiménez-Luna, C.; Diéguez-Castillo, C.; Martín, A.; Prados, J.; Martín-Ruíz, J.L.; Genilloud, O.; Vicente, F.; Palacio, J.P.d.; Caba, O. Untargeted Metabolomics for the Diagnosis of Exocrine Pancreatic Insufficiency in Chronic Pancreatitis. Medicina 2021, 57, 876. https://doi.org/10.3390/ medicina57090876
SponsorshipJUNTA DE ANDALUCIA, grants number PC-0498-2017 and PC-0549-2017; INSTITUTO DE SALUD CARLOS III, grant number DTS17/00081
Background and Objectives: The clinical manifestations and course of chronic pancreatitis (CP) are often nonspecific and variable, hampering diagnosis of the risk of exocrine pancreatic insufficiency (EPI). Development of new, reproducible, and non-invasive methods to diagnose EPI is therefore a major priority. The objective of this metabolomic study was to identify novel biomarkers associated with EPI. Materials and Methods: We analyzed 53 samples from patients with CP, 32 with and 21 without EPI, using an untargeted metabolomics workflow based on hydrophilic interaction chromatography coupled to high-resolution mass spectrometry. Principal component and partial least squares-discriminant analyses showed significant between-group differentiation, and univariate and multivariate analyses identified potential candidate metabolites that significantly differed between samples from CP patients with EPI and those without EPI. Results: Excellent results were obtained using a six-metabolic panel to diagnose the presence of EPI in CP patients (area under the ROC curve = 0.785). Conclusions: This study confirms the usefulness of metabolomics in this disease setting, allowing the identification of novel biomarkers to differentiate between the presence and absence of EPI in CP patients.